Vaccine Schedule Recommendations and Updates for Patients with Hematologic Malignancy Post-hematopoietic Cell Transplant or CAR T-cell Therapy

Overview

Journal Transpl Infect Dis

Specialties General Surgery
Infectious Diseases

Date 2023 Jul 29

PMID 37515788

Authors

Gemma Reynolds

Victoria G Hall

Benjamin W Teh

Affiliations

Soon will be listed here.

Abstract

Revaccination after receipt of a hematopoietic cell transplant (HCT) or cellular therapies is a pillar of patient supportive care, with the potential to reduce morbidity and mortality linked to vaccine-preventable infections. This review synthesizes national, international, and expert consensus vaccination schedules post-HCT and presents evidence regarding the efficacy of newer vaccine formulations for pneumococcus, recombinant zoster vaccine, and coronavirus disease 2019 in patients with hematological malignancy. Revaccination post-cellular therapies are less well defined. This review highlights important considerations around poor vaccine response, seroprevalence preservation after cellular therapies, and the optimal timing of revaccination. Future research should assess the immunogenicity and real-world effectiveness of new vaccine formulations and/or vaccine schedules in patients post-HCT and cellular therapy, including analysis of vaccine response that relates to the target of cellular therapies.

Citing Articles

CD19-directed chimeric antigen receptor T-cell therapy: what can we learn from the haematologist?.

Kuipers M, Kersten M Lupus Sci Med. 2025; 12(1.

PMID: 39832905 PMC: 11751780. DOI: 10.1136/lupus-2024-001157.

Prognostic significance of immune reconstitution following CD19 CAR T-cell therapy for relapsed/refractory B-cell lymphoma.

Stock S, Bucklein V, Blumenberg V, Magno G, Emhardt A, Holzem A Hemasphere. 2025; 9(1):e70062.

PMID: 39807276 PMC: 11726691. DOI: 10.1002/hem3.70062.

Vaccination After Haematopoietic Stem Cell Transplant: A Review of the Literature and Proposed Vaccination Protocol.

Silva-Pinto A, Abreu I, Martins A, Bastos J, Araujo J, Pinto R Vaccines (Basel). 2025; 12(12.

PMID: 39772108 PMC: 11680230. DOI: 10.3390/vaccines12121449.

Recommendations for the effective use of T-cell-redirecting therapies: a Canadian consensus statement.

Lancman G, Song K, White D, Crosbie T, Sharif I, Emond M Front Oncol. 2024; 14:1446995.

PMID: 39659785 PMC: 11628543. DOI: 10.3389/fonc.2024.1446995.

Late complications and long-term care of adult CAR T-cell patients.

Bishop M Hematology Am Soc Hematol Educ Program. 2024; 2024(1):109-115.

PMID: 39643985 PMC: 11665735. DOI: 10.1182/hematology.2024000534.

References

Pollard A, Bijker E . A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol. 2020; 21(2):83-100. PMC: 7754704. DOI: 10.1038/s41577-020-00479-7. View

Sheridan J, Tutschka P, Sedmak D, Copelan E . Immunoglobulin G subclass deficiency and pneumococcal infection after allogeneic bone marrow transplantation. Blood. 1990; 75(7):1583-6. View

Kochenderfer J, Somerville R, Lu T, Yang J, Sherry R, Feldman S . Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. Mol Ther. 2017; 25(10):2245-2253. PMC: 5628864. DOI: 10.1016/j.ymthe.2017.07.004. View

Roberts M, Bak N, Wee L, Chhetri R, Yeung D, Lewis I . Clinical Effectiveness of Conjugate Pneumococcal Vaccination in Hematopoietic Stem Cell Transplantation Recipients. Biol Blood Marrow Transplant. 2019; 26(2):421-427. DOI: 10.1016/j.bbmt.2019.10.006. View

Ng S, Fang V, Ip D, Chan K, Leung G, Peiris J . Estimation of the association between antibody titers and protection against confirmed influenza virus infection in children. J Infect Dis. 2013; 208(8):1320-4. PMC: 3778972. DOI: 10.1093/infdis/jit372. View

Cordonnier C, Ljungman P, Juergens C, Maertens J, Selleslag D, Sundaraiyer V . Immunogenicity, safety, and tolerability of 13-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine in recipients of allogeneic hematopoietic stem cell transplant aged ≥2 years: an open-label study. Clin Infect Dis. 2015; 61(3):313-23. PMC: 4503811. DOI: 10.1093/cid/civ287. View

Nguyen T, Rowntree L, Allen L, Chua B, Kedzierski L, Lim C . Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells. Cell Rep Med. 2023; 4(4):101017. PMC: 10040362. DOI: 10.1016/j.xcrm.2023.101017. View

Trombetta C, Perini D, Mather S, Temperton N, Montomoli E . Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future. Vaccines (Basel). 2015; 2(4):707-34. PMC: 4494249. DOI: 10.3390/vaccines2040707. View

Shem-Tov N, Yerushalmi R, Danylesko I, Litachevsky V, Levy I, Olmer L . Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients. Br J Haematol. 2021; 196(4):884-891. PMC: 8652777. DOI: 10.1111/bjh.17918. View

10.

Logue J, Zucchetti E, Bachmeier C, Krivenko G, Larson V, Ninh D . Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 2020; 106(4):978-986. PMC: 8017820. DOI: 10.3324/haematol.2019.238634. View

11.

Dooling K, Guo A, Patel M, Lee G, Moore K, Belongia E . Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines. MMWR Morb Mortal Wkly Rep. 2018; 67(3):103-108. PMC: 5812314. DOI: 10.15585/mmwr.mm6703a5. View

12.

Camargo J, Lin R, Natori Y, Anderson A, Alencar M, Wang T . Reduced immunogenicity of the adjuvanted recombinant zoster vaccine after hematopoietic cell transplant: a pilot study. Blood Adv. 2020; 4(19):4618-4622. PMC: 7556121. DOI: 10.1182/bloodadvances.2020002269. View

13.

Rotshild V, Hirsh-Raccah B, Miskin I, Muszkat M, Matok I . Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. Sci Rep. 2021; 11(1):22777. PMC: 8611039. DOI: 10.1038/s41598-021-02321-z. View

14.

Chun J, Kim K, Lee M, Kang C, Koh Y, Shin D . Immunogenicity and safety of a live herpes zoster vaccine in hematopoietic stem cell transplant recipients. BMC Infect Dis. 2021; 21(1):117. PMC: 7836155. DOI: 10.1186/s12879-021-05806-4. View

15.

Hall V, Ferreira V, Wood H, Ierullo M, Majchrzak-Kita B, Manguiat K . Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses. Nat Immunol. 2022; 23(3):380-385. DOI: 10.1038/s41590-021-01126-6. View

16.

Anderson T, Masters N, Guo A, Shepersky L, Leidner A, Lee G . Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022; 71(3):80-84. PMC: 8774159. DOI: 10.15585/mmwr.mm7103a2. View

17.

Debbache K, Varon E, Hicheri Y, Legrand P, Donay J, Ribaud P . The epidemiology of invasive Streptococcus pneumoniae infections in onco-haematology and haematopoietic stem cell transplant patients in France. Are the serotypes covered by the available anti-pneumococcal vaccines?. Clin Microbiol Infect. 2009; 15(9):865-8. DOI: 10.1111/j.1469-0691.2009.02810.x. View

18.

Bange E, Han N, Wileyto P, Kim J, Gouma S, Robinson J . CD8 T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021; 27(7):1280-1289. PMC: 8291091. DOI: 10.1038/s41591-021-01386-7. View

19.

Fox T, Kirkwood A, Enfield L, OReilly M, Arulogun S, DSa S . Low seropositivity and suboptimal neutralisation rates in patients fully vaccinated against COVID-19 with B-cell malignancies. Br J Haematol. 2021; 195(5):706-709. PMC: 8653163. DOI: 10.1111/bjh.17836. View

20.

Altarawneh H, Chemaitelly H, Ayoub H, Hasan M, Coyle P, Yassine H . Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants. N Engl J Med. 2022; 387(17):1620-1622. PMC: 9559315. DOI: 10.1056/NEJMc2209306. View